LOVELAND, Colo., Oct. 2, 2012 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska"), a leading provider of advanced diagnostic and specialty products to veterinarians, announced today the expansion of its diagnostic blood analyzer suite. With proven dry chemistry technology and faster time to results, Heska introduces the new Element DC™ Veterinary Chemistry Analyzer. The Element DC will be manufactured by FUJIFILM Corporation. Heska believes blood chemistry represents the largest in-clinic testing market.
"Heska has enhanced our diagnostic line-up with a faster, more efficient point-of-care analyzer," commented Michael McGinley, President and Chief Operating Officer of Heska. "Among other notable features, the Element DC provides high-efficiency throughput, and an enhanced user interface, yielding faster answers for clients and patients. Consistent with our commitment to offer the latest technology in fundamental areas of veterinary medicine, Heska is thrilled to offer this latest generation chemistry analyzer."
Ideally suited for progressive veterinary practitioners who value speed and accuracy, the new Element DC is now available.
About Heska Heska Corporation (NASDAQ: HSKA) sells advanced veterinary diagnostic and specialty products. Heska's state-of-the-art offerings to its customers include diagnostic and monitoring instruments and supplies, allergy testing and treatment, as well as single use point-of-care tests, vaccines and pharmaceuticals. The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at www.heska.com.
Forward-Looking Statements This announcement contains forward-looking statements regarding Heska's future financial and operating results. These statements are based on current expectations and are subject to a number of risks and uncertainties. There are uncertainties regarding Heska's ability to successfully commercialize new products; uncertainties regarding the in-field performance of any new product, including the Element DC; competition, including new products competitors may introduce in the future; uncertainties related to Heska's market estimates; uncertainties regarding Heska's ability to gain market share in an economic manner; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Quarterly Report on Form 10-Q for the three months ended June 30, 2012.
SOURCE Heska Corporation